Effect of cavity absorption on treatment outcomes of Mycobacterium kansasii pulmonary disease

被引:0
|
作者
Zou, Xin [1 ,3 ,5 ]
Yi, Shulin [2 ]
Luo, Mengxing [1 ,3 ]
Zeng, Qibing [3 ]
Yao, Shixiu [4 ]
Chen, Lulu [1 ,3 ]
Yao, Xin [1 ,3 ]
Hu, Yang [1 ]
Liu, Zhonghua [1 ,3 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai Key Lab TB, Shanghai, Peoples R China
[2] Yingtan Peoples Hosp, Dept Resp & Crit Care Med, Yingtan, Peoples R China
[3] Guizhou Med Univ, Sch Publ Hlth, Key Lab Environm Pollut Monitoring & Dis Control, Minist Educ, Guiyang, Peoples R China
[4] Shanghai Jiao Tong Univ, Xinhua Hosp, Clin Res & Innovat Ctr, Sch Med, Shanghai, Peoples R China
[5] Yibin Ctr Dis Control & Prevent, Hlth Surveillance Sect, Yibin 644600, Sichuan, Peoples R China
关键词
Absorption of pulmonary cavities; Effect of treatment; Mycobacterium kansasii; Treatment outcome; CLINICAL-FEATURES; NONTUBERCULOUS MYCOBACTERIA; INFECTION; TUBERCULOSIS;
D O I
10.1016/j.diagmicrobio.2025.116712
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The incidence of Mycobacterium kansasii pulmonary disease (MK-PD) was increasing worldwide. However, limited research was conducted on how to improve the cure rate and evaluate treatment efficacy for patients. We aimed to identify key factors that could improve the cure rate in patients with MK-PD. Methods: In this retrospective cohort study, the medical records of patients with MK-PD, registered with Shanghai Pulmonary Hospital between January 2016 and December 2020, were collected. These included data on demographics, as well as clinical, radiological, microbiological, drug resistance, and drug regimen information, and treatment outcomes. Multivariate logistic regression analysis was conducted to identify risk factors for treatment failure in patients. Results: This study included 129 patients, of whom 100 (77.5 %) were treated successfully. Logistic regression analysis identified non-absorption of pulmonary cavities as an independent risk factor for treatment successful (odds ratio: 7.9, 95 %confidence interval: 1.7-36.2, p = 0.008). The overall cure rate for patients with absorption of pulmonary cavities (APC) was 93 %; 55 % of patients began resorption within 6 months of the start of treatment (the cure rate was 95 %). The APC rate of patients with MK-PD negatively correlated with the number of comorbidities (p = 0.009); that was, the more comorbidities, the more difficult the cavity absorption and the lower the cure rate. Conclusions: The absorption of pulmonary cavities was the key to the cure rate for patients with MK-PD. Early changes in cavities helped identify the effect of treatment and guide doctors in optimizing treatment plans to improve patient cure rates.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Treatment of pulmonary disease caused by Mycobacterium kansasii
    Huang, Hung-Ling
    Lu, Po-Liang
    Lee, Chen-Hsiang
    Chong, Inn-Wen
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 : S51 - S57
  • [2] An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease
    Srivastava, Shashikant
    Pasipanodya, Jotam G.
    Heysell, Scott K.
    Boorgula, Gunavanthi D.
    Gumbo, Tawanda
    McShane, Pamela J.
    Philley, Julie, V
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 28 : 71 - 77
  • [3] IN VITRO ANTIMICROBIAL SUSCEPTIBILITY AND TREATMENT OUTCOMES OF MOLECULAR DIAGNOSED MYCOBACTERIUM KANSASII PULMONARY DISEASE
    Liu, Chia-Jung
    Hsueh, Po-Ren
    Chien, Jung-Yien
    RESPIROLOGY, 2018, 23 : 67 - 67
  • [4] INITIAL TREATMENT IN MYCOBACTERIUM-KANSASII PULMONARY-DISEASE
    MONTANER, LJG
    ABBATE, EH
    BREA, A
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (04): : 202 - 202
  • [5] Pulmonary Mycobacterium kansasii disease in immunocompetent host: Treatment outcomes with short-course chemotherapy
    Padmapriyadarsini, C.
    Nair, D.
    Gomathi, N. S.
    Velayudham, B.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2016, 34 (04) : 516 - 519
  • [6] Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease
    Moon, Seong Mi
    Choe, Junsu
    Jhun, Byung Woo
    Jeon, Kyeongman
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Daley, Charles L.
    Koh, Won-Jung
    RESPIRATORY MEDICINE, 2019, 148 : 37 - 42
  • [7] Clinical Analysis of Pulmonary Mycobacterium kansasii Disease
    Kobashi, Yoshihiro
    Abe, Masaaki
    Yoshioka, Daisuke
    Kato, Shigeki
    Oga, Toru
    AMERICAN JOURNAL OF INFECTIOUS DISEASES, 2020, 16 (01) : 1 - 6
  • [8] Clinical analysis of pulmonary Mycobacterium kansasii disease
    Kobashi, Yoshihiro
    Shirai, Ryo
    Kato, Shigeki
    Oka, Mikio
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [9] Clinical Features Of Mycobacterium Kansasii Pulmonary Disease
    Tsuyuguchi, K.
    Yoshida, S.
    Nakatani, T.
    Inoue, Y.
    Suzuki, K.
    Okada, M.
    Hayashi, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [10] Clinical Characteristics and Treatment Outcomes of Mycobacterium kansasii Lung Disease in Korea
    Park, Hye Kyeong
    Koh, Won-Jung
    Shim, Tae Sun
    Kwon, O. Jung
    YONSEI MEDICAL JOURNAL, 2010, 51 (04) : 552 - 556